Taken together these findings indicate that AR-targeted therapies may increase PI3K/AKT pathway activity by several mechanisms, with decreased ERG expression in T:E fusion tumors being a major mechanism in this tumor subset (Supplemental Figure 12). The gene discussed is AKT1; the disease is neoplasm.